Clinuvel Pharmaceuticals buy MinusSinus
Start price
27.03.25
/
100%
€6.90
Target price
27.04.25
€25.00
Performance (%)
-11.09%
End price
28.04.25
€6.14
Summary
This prediction ended on 28.04.25 with a price of €6.14. The price of Clinuvel Pharmaceuticals has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -11.09%. MinusSinus has a follow-up prediction for Clinuvel Pharmaceuticals where he still thinks Clinuvel Pharmaceuticals is a Buy. MinusSinus has 100% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Clinuvel Pharmaceuticals | -3.740% | -3.740% |
iShares Core DAX® | 0.299% | 2.868% |
iShares Nasdaq 100 | 2.257% | 3.363% |
iShares Nikkei 225® | 5.054% | 8.119% |
iShares S&P 500 | 1.414% | 2.409% |
According to MinusSinus what are the pros and cons of Clinuvel Pharmaceuticals for the foreseeable future?
Pros
Could be very worthwhile Investment >20% year
Rising EBIT margin expected
positive Cash Flow expected
High Investments for future growth
Very valuable balance sheet
ROE higher than 15% per year
Small challenges to pay loans and raise capital
Capable Management
Good culture
Leading role in innovation
Strong uniques
Growths faster than the competition
Stable Large shareholder and/or long term investor
Market Leader or Top 3
Very small cyclical dependencies
Very Future proof/growth oriented business model
Revenue growth >5% per year expected
EBIT growth > 30% per year expected
Top Rating
Differentiated customer and product portfolio
Cons
Very low/no dividend yield expected
Higher risks for its business
Little known brand
Comments by MinusSinus for this prediction
In the thread Clinuvel Pharmaceuticals diskutieren
Kursziel gesetzt auf 25,0
In the thread Trading Clinuvel Pharmaceuticals
Die von MinusSinus gewählte maximale Laufzeit wurde überschritten
Current prediction by MinusSinus for Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals
Start price
Target price
Perf. (%)
€5.99
11.09.25
11.09.25
€9.00
31.12.25
31.12.25
9.10%
08:50
08:50
Could be very worthwhile Investment >20% year
Rising EBIT margin expected
positive Cash Flow expected
Very low/no dividend yield expected